Development of shellfish allergy after exposure to dual immune checkpoint blockade
Autor: | Zachary J Brown, Bernd Heinrich, Tim F Greten |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: | |
Zdroj: | Hepatic Oncology, Vol 5, Iss 1 (2018) |
Druh dokumentu: | article |
ISSN: | 2045-0931 2045-0923 |
DOI: | 10.2217/hep-2017-0021 |
Popis: | Hepatocellular carcinoma (HCC) is a major health problem worldwide with limited systemic therapies available. Immunotherapy is a fast-moving field that is quickly evolving as a treatment for HCC with three recent clinical trials published treating HCC with immune checkpoint inhibitors with promising results. Checkpoint inhibition may lead to a unique adverse event profile with the potential to cause immune-related adverse events by unbalancing the immune system. Here, we report a case of a 61-year-old male with advanced HCC who developed a shellfish allergy after completing three cycles of combination of tremelimumab and durvalumab therapy. |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |